Speaker Profile
Biography
Carolyn R. Bertozzi, a distinguished figure in the field of bioorthogonal chemistry, has made significant contributions to gene and cell therapies across various domains. Her groundbreaking work has earned her the prestigious Nobel Prize, recognizing her innovative techniques that allow precise modification of biomolecules within living cells.
Dr. Bertozzi’s research not only advances our understanding of cellular processes but also provides novel strategies for cell targeting and engineering. Her academic journey began with a focus on chemistry at Harvard University, followed by biochemistry studies at the University of California, Berkeley. Since receiving the Nobel Prize, Dr. Bertozzi has continued to push the boundaries of her field, developing new cancer immunotherapies and point-of-care tests for tuberculosis, and unraveling connections between rare diseases and cancer.
Her remarkable contributions exemplify the intersection of chemistry and biology, revolutionizing therapeutic approaches and paving the way for precision medicine.
Session Abstract – PMWC 2025 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Morten Sogaard, Astellas Gene Therapies
- PMWC 2025 Award Ceremony
Pioneer Honoree: James M. Wilson, Gemma Biotherapeutics
Luminary Honoree: Carolyn Bertozzi, Stanford
- Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation
- Carolyn Bertozzi, Stanford
- Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare
- James M. Wilson, Gemma Biotherapeutics
- Barriers in Gene Therapy
Chair: Timothy Hunt, Alliance for Regenerative Medicine
- Tay Salimullah, 4BIO Capital
- James M. Wilson, Gemma Biotherapeutics - Next-Generation Delivery Systems for Gene Therapies (PANEL)
Chair: Morten Sogaard, Astellas
- Mathieu Nonnenmacher, Voyager Therapeutics
- Kevin Friedman, Kelonia Therapeutics
- Kunwoo Lee, GenEdit
- Haig Aghajanian, Capstan Therapeutics
- James M. Wilson, University of Pennsylvania
- Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment (PANEL)
Chair: Charles Gersbach, Duke
- Prashant Mali, UCSD
- Nadav Ahituv, UCSF
- Blythe Sather, Tune Therapeutics
- Fyodor D Urnov, Berkely University
- Navigating the Regulatory Landscape for Gene and Cell Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC)
- Peter Marks, FDA
- Ben Dewees, Kyverna Therapeutics
- Paul Kruszka, GeneDx
- AI-driven Improvements in Gene and Cell Therapy (PANEL)
Chair: Morten Sogaard, Astellas
- Francois Vigneault, Shape Therapeutics
- John Androsavich, Ginkgo Bioworks
- Eeshit Dhaval Vaishnav, Sequome
- Yogev Debbi, mana.bio